Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

DeRycke MS, Andersen JD, Harrington KM, Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA, Skubitz AP.

Am J Clin Pathol. 2009 Dec;132(6):846-56. doi: 10.1309/AJCPTK87EMMIKPFS.

2.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

3.

AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Yang F, Guo X, Yang G, Rosen DG, Liu J.

Mod Pathol. 2011 Jun;24(6):836-45. doi: 10.1038/modpathol.2011.44. Epub 2011 Mar 25.

4.

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.

Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ.

Clin Cancer Res. 2005 Sep 15;11(18):6422-30.

5.

Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R.

Int J Cancer. 2013 Apr 1;132(7):1633-45. doi: 10.1002/ijc.27840. Epub 2012 Oct 17.

6.

beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Moreno-Bueno G, Gamallo C, Pérez-Gallego L, de Mora JC, Suárez A, Palacios J.

Diagn Mol Pathol. 2001 Jun;10(2):116-22.

PMID:
11385321
7.

Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH.

Int J Gynecol Cancer. 2016 Jan;26(1):125-32. doi: 10.1097/IGC.0000000000000563.

8.

Identification of a gene expression signature for survival prediction in type I endometrial carcinoma.

Levan K, Partheen K, Osterberg L, Olsson B, Delle U, Eklind S, Horvath G.

Gene Expr. 2010;14(6):361-70.

PMID:
20635577
9.

Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.

Guirguis A, Elishaev E, Oh SH, Tseng GC, Zorn K, DeLoia JA.

Gynecol Oncol. 2008 Feb;108(2):370-6.

PMID:
18083218
10.

DEF6 expression in ovarian carcinoma correlates with poor patient survival.

Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.

Diagn Pathol. 2016 Aug 3;11(1):68. doi: 10.1186/s13000-016-0518-y.

11.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549
12.

Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.

Kelemen LE, Rambau PF, Koziak JM, Steed H, Köbel M.

Cancer Causes Control. 2017 May;28(5):447-457. doi: 10.1007/s10552-017-0855-5. Epub 2017 Feb 13.

PMID:
28194593
13.

Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.

Watari H, Xiong Y, Hassan MK, Sakuragi N.

Gynecol Oncol. 2009 Jan;112(1):229-34. doi: 10.1016/j.ygyno.2008.09.039. Epub 2008 Nov 12.

PMID:
19007976
14.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.

PMID:
19967725
15.

Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.

Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS.

Cancer Biol Ther. 2009 Nov;8(22):2126-35. Epub 2009 Nov 5.

16.

Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J.

Eur J Gynaecol Oncol. 2015;36(3):260-7.

PMID:
26189250
17.

[The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].

Gottwald L, Kubiak R, Sek P, Piekarski J, Szwalski J, Pasz-Walczak G, Spych M, Suzin J, Tylińskis W, Jeziorski A.

Ginekol Pol. 2013 Jun;84(6):444-9. Polish.

PMID:
24032262
18.

Hypomethylation-induced expression of S100A4 in endometrial carcinoma.

Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR.

Mod Pathol. 2007 Oct;20(10):1045-54. Epub 2007 Aug 3.

19.

Prognostic value of Musashi-1 in endometrioid adenocarcinoma.

Ma L, Xu YL, Ding WJ, Shao HF, Teng YC.

Int J Clin Exp Pathol. 2015 May 1;8(5):4564-72. eCollection 2015.

20.

Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.

Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, Berkowitz RS, Mok SC.

Med Oncol. 2006;23(2):205-12.

PMID:
16720920

Supplemental Content

Support Center